AUP Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.

Wednesday, November 14, 2018, Aurinia will present a company overview at the Jefferies 2018 London Healthcare Conference in London, UK at 10:00am GMT. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archived on the site following the event.

Tuesday, November 27, 2018, Aurinia will participate in One-on-One Meetings at the Evercore ISI HealthCONx Conference in Boston, MA.

About Aurinia

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

We seek safe harbor.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005133/en/

Investor:Celia EconomidesVP, Corporate & Public AffairsIR@auriniapharma.comorMedia:Christopher Hippolyte, 212-364-0458Christopher.hippolyte@inventivhealth.com

Aurinia Pharmaceuticals (TSXV:AUP)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

Aurinia Pharmaceuticals (TSXV:AUP)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024